BURLINGTON, Mass., July 10, 2014 /PRNewswire/ -- Decision Resources Group finds that over half of surveyed nephrologists report awareness of the U.S. Food and Drug Administration's (FDA) approval of Vifor Fresenius Medical Care Renal Pharma's new phosphate binder Velphoro, which was approved by the FDA in November 2013 for the treatment of hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
Other key findings from the report entitled TreatmentTrends: Nephrology (US) Q2 2014:
Comments from Decision Resources Group Director Rob Dubman:
A special report that is expected to publish later this month entitled The Impact of New Iron-Based Phosphate Binders on the Hyperphosphatemia Market will also help manufacturers understand why and how Velphoro and Keryx Pharmaceutical's Zerenex will be used, if Zerenex receives FDA approval later this year.
About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact:
Decision Resources Group
|SOURCE Decision Resources Group|
Copyright©2014 PR Newswire.
All rights reserved